An allogeneic stem cell-derived transplant, OPC1 helps restore or increase the functional activity in SCI patients. It is tailored to replace the spinal cord cells that are either ...

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic ...

More than 15 million people worldwide are living with spinal cord injury (SCI), which can affect their sensory and motor ...

Lineage Cell Therapeutics (LCTX) announced that the Company has initiated the DOSED clinical study. The DOSED study will evaluate the safety ...

Spinal cord injury (SCI) remains the most serious complication of repairing descending thoracic and thoracoabdominal aortic aneurysms, with endovascular ...

Nerve cells in the spinal cord do not regenerate easily and scar tissue forms quickly ... and improving recovery. Shortly after the injury, steroid medications and surgery are used to help reduce ...

A neurosurgeon and a neuroscientist discover promising new ways to help people with spinal cord injuries walk again ...

Three people with a muscle-destroying disease destined to worsen got a little stronger when an implanted device zapped their ...

Finally, metastasis results when tumor cells in the cerebrospinal fluid ... a true emergency because the initial injury to the spinal cord will lead to permanent loss of neurologic function ...

Lineage Cell Therapeutics initiates DOSED clinical study of OPC1 for spinal cord injury: Carlsbad, California Thursday, February 13, 2025, 14:00 Hrs [IST] Lineage Cell Therapeutic ...